#USA #Mt. Pleasant #Epidermolysis Bullosa #Paradigm Therapeutics #SD-101

Paradigm Therapeutics Secures $12.6 Million Investment from Eshelman Ventures

Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a significant boost to its funding with an additional investment of $12.6 million from Eshelman Ventures, LLC. This strategic funding is set to enhance the development and global registration of SD-101, a topical therapy targeting all subtypes of Epidermolysis Bullosa (EB), a rare and debilitating genetic skin disorder.

Advancements in EB Treatment Technology

The new injection of funds elevates the total investment for Paradigm Therapeutics in 2025 to an impressive $25.1 million. With this funding, Paradigm aims to accelerate activities associated with the manufacturing and commercial launch of SD-101 across global markets. Dr. A.S. Eshelman will continue to serve as a strategic advisor, contributing his insights during this critical development phase.

SD-101 is being developed as a comprehensive topical body treatment for patients suffering from all subtypes of Epidermolysis Bullosa. Currently, the treatment landscape for EB is severely limited, with no approved therapies that adequately address the needs of these patients. Paradigm Therapeutics seeks to change this by working closely with regulatory bodies worldwide to ensure that patients receive the best possible care, regardless of their specific subtype classification.

Dr. Robert Ryan, the CEO of Paradigm Therapeutics, expressed optimism about the new investment, stating, "The opportunity to secure additional investment for the SD-101 program will allow Paradigm to fast-track our efforts as we strive to bring SD-101 to Epidermolysis Bullosa patients globally." He emphasized the company's commitment to collaborating with regulatory authorities to fill the existing treatment gap for EB patients.

Clinical Promise of SD-101

The need for effective treatments for Epidermolysis Bullosa cannot be overstated. This genetic condition often results in extremely fragile skin that is susceptible to blisters and open wounds from birth, significantly affecting the quality of life for patients and their families. The chronic nature of EB can lead to pain, disfigurements, and even life-threatening infections, creating a dire need for innovative therapeutic solutions.

Recent clinical trials conducted in the United States and Europe have shown promising outcomes for SD-101 in treating EB. Phase II and Phase III studies demonstrated substantial benefits in terms of skin healing for both pediatric and adult patients, who frequently lack access to comprehensive body treatments. The results indicate that SD-101 not only boosts healing but also possesses a favorable safety profile even with long-term use.

Furthermore, one of the most noteworthy findings from these trials is that SD-101 helps reduce the incidence of skin infections, which are major contributors to morbidity and mortality in the EB patient population. These findings underscore the potential of SD-101 to truly impact the lives of those suffering from this condition.

About Epidermolysis Bullosa

Epidermolysis Bullosa is a rare genetic disorder characterized by exceptionally fragile skin. Patients with EB can experience severe blistering and open wounds that are often debilitating and may lead to additional complications over time. The condition affects individuals across a spectrum of severity, and the lack of approved and effective treatments for the complete coverage of skin manifestations presents a significant challenge within the medical community.

About SD-101 and Paradigm Therapeutics

SD-101 is a groundbreaking topical cream that promises to address the severe skin conditions related to all subtypes of Epidermolysis Bullosa. The therapy has undergone rigorous clinical testing, involving 217 patients across multiple studies. The treatment requires no special handling and can be stored at room temperature, making it practical for daily use.

As Paradigm Therapeutics continues to navigate the complex landscape of drug development, the company remains focused on fulfilling its mission to revolutionize care for patients battling rare diseases such as EB. With SD-101 showing considerable promise, it is positioned to emerge as a critical tool in the therapeutic arsenal against Epidermolysis Bullosa, potentially changing lives for the better.

The future is bright for Paradigm and its groundbreaking therapy SD-101, as they work towards approval and greater accessibility for all patients in need.